DexCom, Inc. (NASDAQ:DXCM) Receives Average Rating of "Moderate Buy" from Brokerages

Key Points

• DexCom has a “Moderate Buy” consensus rating from 27 brokerages, with 21 buy ratings and two strong-buy ratings. The average 12-month price target is $88.71.
• DexCom reported quarterly EPS of $0.70, beating estimates of $0.61, while revenue rose 13.1% year over year to $1.31 billion. Shares opened at $90.82, near the company’s 52-week high of $92.59.
• Insiders sold 75,600 shares worth approximately $5.67 million during the last quarter, while institutional investors own 97.75% of DexCom’s outstanding stock.

Shares of DexCom, Inc. (NASDAQ:DXCM - Get Free Report) have been assigned an average rating of "Moderate Buy" from the twenty-seven brokerages that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, twenty-one have assigned a buy rating and two have assigned a strong buy rating to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $88.7083.

Several brokerages recently weighed in on DXCM. Piper Sandler reissued an "overweight" rating and issued a $95.00 price objective (up from $88.00) on shares of DexCom in a report on Friday, July 31st. BTIG Research reaffirmed a "buy" rating and set a $90.00 price objective (up from $80.00) on shares of DexCom in a report on Friday, July 31st. Truist Financial set a $93.00 price objective on shares of DexCom and gave the stock a "buy" rating in a report on Friday, July 31st. Wall Street Zen lowered DexCom from a "buy" rating to a "hold" rating in a report on Saturday. Finally, JPMorgan Chase & Co. raised their price objective on shares of DexCom from $65.00 to $82.00 and gave the company a "neutral" rating in a research report on Friday, July 31st.

DexCom Price Performance

Shares of NASDAQ DXCM opened at $90.82 on Monday. The stock has a fifty day simple moving average of $79.21 and a two-hundred day simple moving average of $71.61. DexCom has a 1-year low of $54.11 and a 1-year high of $92.59. The firm has a market cap of $34.27 billion, a price-to-earnings ratio of 35.90, a price-to-earnings-growth ratio of 1.53 and a beta of 1.41. The company has a current ratio of 1.73, a quick ratio of 1.43 and a debt-to-equity ratio of 0.47.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.61 by $0.09. DexCom had a return on equity of 35.94% and a net margin of 20.12%.The firm had revenue of $1.31 billion for the quarter, compared to analyst estimates of $1.29 billion. During the same period in the previous year, the company posted $0.48 earnings per share. The business's revenue was up 13.1% on a year-over-year basis. Analysts anticipate that DexCom will post 2.64 earnings per share for the current year.

Insider Transactions at DexCom

In related news, insider Kevin R. Sayer sold 26,756 shares of the business's stock in a transaction dated Monday, July 20th. The stock was sold at an average price of $76.32, for a total transaction of $2,042,017.92. Following the completion of the transaction, the insider directly owned 328,970 shares in the company, valued at $25,106,990.40. The trade was a 7.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Jon Brown sold 1,700 shares of the company's stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $75.55, for a total value of $128,435.00. Following the completion of the transaction, the executive vice president owned 106,353 shares in the company, valued at $8,034,969.15. This represents a 1.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 75,600 shares of company stock valued at $5,673,342. Corporate insiders own 0.28% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Reflection Asset Management bought a new position in shares of DexCom during the 4th quarter valued at about $25,000. Ascentis Independent Advisors purchased a new stake in DexCom during the first quarter valued at about $25,000. MCF Advisors LLC bought a new position in shares of DexCom during the fourth quarter valued at about $32,000. Wellington Grp LLC grew its stake in shares of DexCom by 778.7% during the first quarter. Wellington Grp LLC now owns 536 shares of the medical device company's stock valued at $34,000 after buying an additional 475 shares during the last quarter. Finally, DV Equities LLC bought a new stake in shares of DexCom in the 4th quarter valued at about $36,000. 97.75% of the stock is currently owned by institutional investors.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company's offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source